SYNCHRONIZE-1: Survodutide Hits 16.6% Weight Loss in Phase 3
Published: April 29, 2026 · 4 min read · By Grey Peptides News Desk · ✓ Sourced
On April 28, 2026, Boehringer Ingelheim and Zealand Pharma announced positive topline results from SYNCHRONIZE-1, the first Phase 3 obesity trial of survodutide — a once-weekly glucagon/GLP-1 dual receptor agonist. Adults with obesity or overweight without type 2 diabetes lost an average of 16.6% of body weight at 76 weeks (efficacy estimand) versus 3.2% on placebo, and up to 85.1% achieved at least 5% weight loss. The trial met its co-primary endpoints and a key secondary endpoint on waist circumference. Survodutide is investigational and not approved anywhere.
The mechanism
Survodutide (BI 456906) activates two receptors: GLP-1, the target shared by semaglutide and the GLP-1 arm of tirzepatide, and glucagon, which can raise energy expenditure and has drawn particular interest for liver fat. That glucagon component is why the program is also being studied in metabolic dysfunction-associated steatohepatitis (MASH), and why the companies emphasized "metabolic health" — not just the scale reading — in how they framed the result. Initial analysis indicated the weight loss was driven predominantly by fat rather than lean mass.
How to read 16.6%
On its own, the figure is solid: it edges past semaglutide at the licensed 2.4 mg Wegovy dose (about 14.9% in STEP-1) and clears the threshold for a clinically meaningful obesity therapy. But it sits below several competitors — tirzepatide (around 20.9% in SURMOUNT-1), the higher-dose Wegovy 7.2 mg (20.7% in STEP UP), CagriSema (about 20.4% in REDEFINE-1), and well below retatrutide's recent Phase 3 readout. As analysts noted, the placebo-adjusted figure of roughly 13.4% in a population of around 725 adults looked relatively undifferentiated on weight loss alone.
What the topline didn't answer
Several questions stay open until the full dataset. The waist-circumference benefit was reported as statistically significant but without the underlying numbers. Tolerability is the bigger unknown: an earlier Phase 2 study saw about a quarter of patients discontinue, and the companies had signaled that more flexible titration and anti-nausea support might improve that in Phase 3 — whether it did isn't yet clear from the topline. And survodutide's potential edge may lie less in weight loss than in liver and cardiometabolic endpoints, which this obesity trial wasn't designed to settle.
What's next
Full SYNCHRONIZE-1 data are scheduled for the American Diabetes Association 2026 Scientific Sessions in June, with additional trials across the obesity program — including populations with comorbidities and a separate type 2 diabetes study (SYNCHRONIZE-2) — reading out later in the year. For now, survodutide remains an investigational agent: not approved, not prescribable, and still establishing where it fits in an increasingly crowded incretin field.
Related on Grey Peptides
Glucagon/GLP-1 dual-agonist mechanism, MASH program, and trial history. Glucagon — Encyclopedia entry
Why adding glucagon-receptor activity changes the metabolic profile of an incretin. Peptide Comparison Tool
Line survodutide up against the approved and investigational incretins.
Boehringer Ingelheim — Phase III SYNCHRONIZE-1 obesity trial results ↗
Topline release: April 28, 2026, Ingelheim, Germany. Survodutide (BI 456906) co-developed by Boehringer Ingelheim and Zealand Pharma. Full data expected at ADA 2026.